Contact
searchSearch
HMP Global
Login

Treatment

Treatment
Encompasses all therapeutic interventions tailored to effectively treat cancer.

News
McKesson Report Details Key Trends Shaping US Community Oncology Care
01/14/2026
Grace Taylor, MS, MA
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community...
01/14/2026
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Progression-Free Survival in NSCLC: Clinical Utility, Limitations, and Evolving Standards
10/15/2025
Rajat Thawani, MD
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key...
10/15/2025
Journal of Clinical Pathways
Original Research
Standardizing Somatic and Germline Molecular Testing in Prostate Cancer: Care Pathway and EHR Applications
10/15/2025
Mehmet Asim Bilen, MD; Aleksandar Zafirovski, MBA; Robert A. Bailey, MD; Ibrahim Khilfeh, PharmD; Urmi Bapat, MD; Kyra Svoboda, BS; Michael Kramer, MD, MBA
This study presents the development of an evidence-informed care pathway and EHR-integrated tools to standardize tumor and germline testing workflows for patients with metastatic prostate cancer.
This study presents the development of an evidence-informed care pathway and EHR-integrated tools to standardize tumor and germline testing workflows for patients with metastatic prostate cancer.
This study presents the...
10/15/2025
Journal of Clinical Pathways
Original Research
Real-World Outcomes of Next-Generation Sequencing of Progressive Radioactive Iodine Refractory Metastatic Thyroid Cancer and Treatment of These Patients With Redifferentiation Protocol
10/15/2025
Jennifer Wheeley, MS, FNP-C; Nikita Chintapally, MD; Kanchan Kulkarni, MD; Gabriel Yohe, MS; Priya Kundra, MD; Jennifer Rosen, MD; Muhammad M. Shaikh, MD; Meeta Sharma, MD; Jason Wexler, MD; Kenneth D. Burman, MD; Leila Shobab, MD; Irina Veytsman, MD
In this study, targeted redifferentiation with BRAF and MEK inhibition restored radioactive iodine avidity in the majority of patients with refractory differentiated thyroid cancer, highlighting a promising therapeutic approach.
In this study, targeted redifferentiation with BRAF and MEK inhibition restored radioactive iodine avidity in the majority of patients with refractory differentiated thyroid cancer, highlighting a promising therapeutic approach.
In this study, targeted...
10/15/2025
Journal of Clinical Pathways
Abstracts
Cost-Effectiveness of BTKis in Medicare Patients With CLL in First-Line and Relapsed/Refractory Settings
08/25/2025
Bhavini Srivastava, MSc; Huimin Li, MA; Pam Martin, PhD; James Gahn, BS; Shaffee Bacchus, PharmD; Erin Franceschini, MS; Kavita Sail, PhD
Using a semi-Markov model from a US Medicare perspective, ibrutinib priced at the Centers for Medicare & Medicaid Services–negotiated maximum fair price (MFP) was found to be cost-effective compared with acalabrutinib and zanubrutinib at...
Using a semi-Markov model from a US Medicare perspective, ibrutinib priced at the Centers for Medicare & Medicaid Services–negotiated maximum fair price (MFP) was found to be cost-effective compared with acalabrutinib and zanubrutinib at...
Using a semi-Markov model from a...
08/25/2025
Journal of Clinical Pathways
Abstracts
Decision Support Documentation for Targeted Therapy Eligibility in Breast Cancer
08/25/2025
Daniel Rubin, PharmD, BCOP; Victoria Handy, PharmD, BCOP; Steven Gilmore, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS
Re-prompting providers within the Clear Value Plus clinical decision support system significantly improved documentation of AKT1, PTEN, and PIK3CA biomarkers and increased the use of precision therapies for hormone receptor–positive,...
Re-prompting providers within the Clear Value Plus clinical decision support system significantly improved documentation of AKT1, PTEN, and PIK3CA biomarkers and increased the use of precision therapies for hormone receptor–positive,...
Re-prompting providers within...
08/25/2025
Journal of Clinical Pathways
Abstracts
Modification of PARP Inhibitor Use in mCRPC With Co-Occurring BRCA1/2 Mutations and MSI-High Status
08/25/2025
Steven Gilmore, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS; Victoria Handy, PharmD, BCOP; Daniel Rubin, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Dhaval Shah, MBBS
Following an update to the US Oncology Network’s Prostate Cancer Pathway reflecting evidence that BRCA1/2 mutations in microsatellite instability–high (MSI-H) tumors are typically monoallelic and not associated with PARP inhibitor...
Following an update to the US Oncology Network’s Prostate Cancer Pathway reflecting evidence that BRCA1/2 mutations in microsatellite instability–high (MSI-H) tumors are typically monoallelic and not associated with PARP inhibitor...
Following an update to the US...
08/25/2025
Journal of Clinical Pathways
Abstracts
Efficacy, Safety, and End-of-Treatment Mutational Results From the 5-Year Follow-Up of the Phase 2 OPTIC Study in Patients With Chronic-Phase Chronic Myeloid Leukemia
08/25/2025
Jorge Cortes, MD; Michael Deininger, MD, PhD; Jane Apperley, MD; Andreas Hochhaus, MD; Hugues de Lavallade, MD, PhD; Jeffrey Lipton, MD, PhD; Elza Lomaia, MD, PhD; James McCloskey, MD; Lori Maness, MD; Michael Mauro, MD; Beatriz Moiraghi, MD; Carolina Pavlovsky, MD; Gianantonio Rosti, MD; Philippe Rousselot, MD, PhD; Maria Undurraga Sutton, MD; Bo Chao, MS; Alexander Vorog, MD; Tammie Yeh, PhD; Niti Patel, PhD; Hagop Kantarjian, MD
The 5-year results of the OPTIC study demonstrate that a response-based dosing strategy of ponatinib—starting at 45 mg daily and reducing to 15 mg upon achieving major molecular response—provides sustained efficacy and manageable safety in...
The 5-year results of the OPTIC study demonstrate that a response-based dosing strategy of ponatinib—starting at 45 mg daily and reducing to 15 mg upon achieving major molecular response—provides sustained efficacy and manageable safety in...
The 5-year results of the OPTIC...
08/25/2025
Journal of Clinical Pathways
Research Reports
An Oncology Provider-Driven Model to Implement Germline Genetic Testing Among Diverse Patients With Advanced Prostate Cancer
08/15/2025
Lisa Nuccio, MSN, FNP-C; Kirsten Drabek, BS; Neha Hippalgaonkar, MD; Aseem Tiwari, MPH, MD, MBBS; Vivian Pan, MS, PhD; Kent Hoskins, MD; Pamela Ganschow, MD; Tara Maga, PhD, MS; Lara Balay, MS Ed, MS, CGC; Karine Tawagi, MD; Natalie Reizine, MD
In this study, researchers examine the clinical implementation of an oncology-directed model of delivering guideline-concordant germline genetic testing in patients living with and receiving standard-of-care treatment for advanced prostate...
In this study, researchers examine the clinical implementation of an oncology-directed model of delivering guideline-concordant germline genetic testing in patients living with and receiving standard-of-care treatment for advanced prostate...
In this study, researchers...
08/15/2025
Journal of Clinical Pathways
Research Reports
Oncology Pathways Drive Adoption of High-Quality Treatment Regimens and Deliver Drug Cost Savings
08/15/2025
Kathryn Christensen, MD, MS; Timothy Dollear, MD, MS; Rama Al Ghannam, PharmD; Eric Gratias, MD, FAAP; Robinson Ortiz, MD; Stephen Hamilton, MD
Kathryn Christensen, MS, and colleagues share the initial results of the launch of Cigna and eviCore Healthcare’s Oncology Value-based Pathways program.
Kathryn Christensen, MS, and colleagues share the initial results of the launch of Cigna and eviCore Healthcare’s Oncology Value-based Pathways program.
Kathryn Christensen, MS, and...
08/15/2025
Journal of Clinical Pathways
JCP Nov-Dec Cover

Current Issue

December 2025
Volume 11
Issue 6
Current Issue
Issue Archive

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use